AllPennyStocks.com ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’

ARCT stock was most recently buoyed by positive late-stage results from Merck and Moderna on their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.

Other Penny Stock Movers

65,000 Patients a Year, Zero Approved Drugs, One Phase 3 Trial
$4.5 Million Could Unlock a Major Cannabis Market
Chilean Gold Developer Gains 15% on Final Permit Clearance
Most Popular
{{ index + 1 }}


Back to Top